Publicacións en colaboración con investigadores/as de Hospital Clinic Barcelona (13)

2021

  1. Effects of covid-19 lockdown on tumour burden of melanoma and cutaneous squamous cell carcinoma

    Acta Dermato-Venereologica, Vol. 101, Núm. 8

  2. Food groups associated with immune-mediated inflammatory diseases: a Mendelian randomization and disease severity study

    European Journal of Clinical Nutrition, Vol. 75, Núm. 9, pp. 1368-1382

2019

  1. Genetic variation at the glycosaminoglycan metabolism pathway contributes to the risk of psoriatic arthritis but not psoriasis

    Annals of the Rheumatic Diseases, Vol. 78, Núm. 3, pp. 355-364

  2. Survival analysis and sentinel lymph node status in thin cutaneous melanoma: A multicenter observational study

    Cancer Medicine, Vol. 8, Núm. 9, pp. 4235-4244

2017

  1. Cardiovascular disease in immune-mediated inflammatory diseases: A cross-sectional analysis of 6 cohorts

    Medicine (United States), Vol. 96, Núm. 26

  2. Tratamiento del carcinoma de mama en tejido mamario ectópico axilar

    Cirugia Espanola, Vol. 95, Núm. 4, pp. 232-233

2016

  1. Urine metabolome profiling of immune-mediated inflammatory diseases

    BMC Medicine, Vol. 14, Núm. 1

2015

  1. A deletion at adamts9-magi1 locus is associated with psoriatic arthritis risk

    Annals of the Rheumatic Diseases, Vol. 74, Núm. 10, pp. 1875-1881

2014

  1. Directrices del grupo español de psoriasis (GEP) basadas en la evidencia para el uso de medicamentos biológicos en pacientes con psoriasis en localizaciones de difícil tratamiento (uñas, cuero cabelludo, palmas y plantas)

    Actas Dermo-Sifiliograficas

2013

  1. Spanish evidence-based guidelines on the treatment of psoriasis with biologic agents, 2013. Part 1: On efficacy and choice of treatment

    Actas Dermo-Sifiliograficas

2012

  1. Risk variants for psoriasis vulgaris in a large case-control collection and association with clinical subphenotypes

    Human Molecular Genetics, Vol. 21, Núm. 20, pp. 4549-4557

2011

  1. Clinical characteristics and disease course in patients treated with efalizumab following suspension of marketing authorization by the European Medicines Agency: A multicenter observational study

    Actas Dermo-Sifiliograficas, Vol. 102, Núm. 5, pp. 354-364

1991

  1. Ebastine in chronic urticaria: A double-blind placebo-controlled study

    Journal of Dermatological Treatment, Vol. 2, Núm. 2, pp. 51-53